Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results

Rhea-AI Summary

Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on developing novel oncology therapies, has announced its plans to release its second quarter 2024 financial results. The company will report these results after the U.S. financial markets close on Thursday, August 8, 2024. Following the release, Oncternal's management team will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the financial results in detail. Investors and interested parties can access the live webcast through the company's investor relations website at investor.oncternal.com. The webcast will remain archived on the site for a minimum of 30 days for those unable to attend the live event.

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets close on Thursday, August 8, 2024. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s financial results.

The live webcast of the call will be available online at investor.oncternal.com and will be archived there for at least 30 days.

About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. ONCT-534 is an investigational dual-action androgen receptor inhibitor (DAARI) with demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR aberration. It is a potential treatment for patients with mCRPC with unmet medical need because of resistance to androgen receptor pathway inhibitors, including those with AR amplification, mutations in the AR ligand binding domain (LBD), or splice variants with loss of the AR LBD. Study ONCT-534-101 (NCT05917470) has completed enrollment and dosing in six dose cohorts for the treatment of patients with mCRPC. ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding domain from zilovertamab. ONCT-808 has demonstrated activity in preclinical models against multiple hematological malignancies and solid tumors and has been shown to be specific for cancer cells expressing ROR1. Oncternal has developed a robust and reproducible manufacturing process that has the potential to reduce the time patients must wait for their individual CAR T therapy to be produced, compared with currently approved CAR T products. Oncternal has dosed patients under Study ONCT-808-101 (NCT05588440) with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of ROR1. Zilovertamab has been evaluated in a Phase 1/2 Study CIRM-0001 (NCT03088878) in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL), which resulted in 100% progression free survival (PFS) at 42 months in CLL patients expressing a p53 mutation/del(17p), a population underserved by current treatment options. Zilovertamab is also being evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (NCT05156905). More information on our company and programs is available at https://oncternal.com/.

Contact Information:

Investors
Richard Vincent
858-434-1113
rvincent@oncternal.com

Media
Corey Davis, Ph.D.         
LifeSci Advisors         
212-915-2577        
cdavis@lifesciadvisors.com

FAQ

When will Oncternal Therapeutics (ONCT) report its Q2 2024 financial results?

Oncternal Therapeutics (ONCT) will report its second quarter 2024 financial results after the U.S. financial markets close on Thursday, August 8, 2024.

What time is Oncternal Therapeutics' (ONCT) Q2 2024 earnings webcast scheduled for?

Oncternal Therapeutics' (ONCT) Q2 2024 earnings webcast is scheduled for 2:00 p.m. PT (5:00 p.m. ET) on Thursday, August 8, 2024.

Where can I access Oncternal Therapeutics' (ONCT) Q2 2024 earnings webcast?

You can access Oncternal Therapeutics' (ONCT) Q2 2024 earnings webcast live at investor.oncternal.com. The webcast will also be archived there for at least 30 days.

What will be discussed during Oncternal Therapeutics' (ONCT) Q2 2024 earnings call?

During the Q2 2024 earnings call, Oncternal Therapeutics' (ONCT) management will provide a business update and discuss the company's financial results for the second quarter of 2024.